Rola BCG w zapobieganiu gruźlicy i strategie prowadzące do zwiększenia jej immunogenności

Autor

  • Jolanta Mazurek Karolinska Institutet, Centrum Medycyny Zakaźnej, Sztokholm, Szwecja

DOI:

https://doi.org/10.5604/01.3001.0012.1373

Słowa kluczowe:

gruźlica, szczepionka, BCG, Mycobacterium tuberculosis

Abstrakt

Gruźlica pozostaje ważnym problemem zdrowia publicznego i jest główną przyczyną zgonów z powodu chorób zakaźnych na całym świecie. Mycobacterium tuberculosis (Mtb), bakteria wywołująca gruźlicę, jest najstarszym znanym ludzkim patogenem. Jedyną dostępną szczepionkę przeciwgruźliczą, BCG, po raz pierwszy zastosowano już w 1921 r. i od tego czasu pozostaje ona jedynym narzędziem zapobiegającym gruźlicy. Jej skuteczność jest jednak ograniczona i istnieje pilna potrzeba zaprojektowania i wyprodukowania nowej szczepionki, która chroni przed tą śmiercionośną chorobą, szczególnie w dobie pojawiających się problemów z antybiotykoopornością Mtb. W niniejszej pracy przeglądowej opisano aktualną, globalną sytuację epidemiologiczną dotyczącą gruźlicy i przedstawiono charakterystykę BCG. Opisano także strategie prowadzące do wytworzenia wariantów BCG zapewniających lepszą ochronę przeciwgruźliczą.

Pobrania

Statystyki pobrań niedostępne.

Bibliografia

Koch R. (1882). Die Aetiologie der Tuberkulose, Berl. Klin. Wochenschr, 19, 221–230.

Comas, I., Coscolla, M., Luo, T., Borrell, S., Holt, K. E., Kato-Maeda, M., ... & Yeboah-Manu, D. (2013). Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nature genetics, 45(10), 1176.

WHO, Global tuberculosis report 2017., World Health Organization, Global tuberculosis report 2017. Geneva, Switzerland, 2017.

Tuberculosis surveillance and monitoring in Europe Centre for Disease Prevention and Control/WHO Regional Office for Europe., Stockholm: European Centre for Disease Prevention and Control, 2015.

Getahun, H., Matteelli, A., Abubakar, I., Aziz, M. A., Baddeley, A., Barreira, D., ... & Cavalcante, S. (2015). Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. European Respiratory Journal, 1563–1576.

Russell, D. G., Barry, C. E., & Flynn, J. L. (2010). Tuberculosis: what we don’t know can, and does, hurt us. Science, 328(5980), 852–856.

Lange, C., Chesov, D., Heyckendorf, J., Leung, C. C., Udwadia, Z., & Dheda, K. (2018). Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology.

Nieuwenhuizen, N.E., Kaufmann, S.H.E. (2018). Next-Generation Vaccines Based on Bacille Calmette-Guerin, Front Immunol, 9, 121.

Kaufmann, S. H., Weiner, J., & von Reyn, C. F. (2017). Novel approaches to tuberculosis vaccine development. International Journal of Infectious Diseases, 56, 263–267.

Brosch, R., Gordon, S. V., Marmiesse, M., Brodin, P., Buchrieser, C., Eiglmeier, K., … & Parsons, L. M. (2002). A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proceedings of the national academy of Sciences, 99(6), 3684–3689.

Ganguly, N., Siddiqui, I., & Sharma, P. (2008). Role of M. tuberculosis RD-1 region encoded secretory proteins in protective response and virulence. Tuberculosis, 88(6), 510–517.

Pym, A. S., Brodin, P., Brosch, R., Huerre, M., & Cole, S. T. (2002). Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Molecular microbiology, 46(3), 709–717.

Fine, P. E. (1995). Variation in protection by BCG: implications of and for heterologous immunity. The Lancet, 346(8986), 1339–1345.

Adinarayanan, S., Culp, R. K., Subramani, R., Abbas, K. M., Radhakrishna, S., & Swaminathan, S. (2017). Role of bacille Calmette-Guérin in preventing tuberculous infection. The International Journal of Tuberculosis and Lung Disease, 21(4), 420–424.

Hart, P. D. A., & Sutherland, I. (1977). BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J, 2(6082), 293–295.

Rodrigues, L. C., Diwan, V. K., & Wheeler, J. G. (1993). Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. International journal of epidemiology, 22(6), 1154–1158.

Trunz, B. B., Fine, P. E. M., & Dye, C. (2006). Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. The Lancet, 367(9517), 1173–1180.

WHO, BCG vaccine: WHO position paper, February 2018 – Recommendations, Vaccine, (2018).

Zwerling, A., Behr, M. A., Verma, A., Brewer, T. F., Menzies, D., & Pai, M. (2011). The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS medicine, 8(3), e1001012.

Kleinnijenhuis, J., Quintin, J., Preijers, F., Benn, C. S., Joosten, L. A., Jacobs, C., ... & Van Crevel, R. (2014). Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. Journal of innate immunity, 6(2), 152–158.

Garly, M. L., Martins, C. L., Balé, C., Baldé, M. A., Hedegaard, K. L., Gustafson, P., ... & Aaby, P. (2003). BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa: a non-specific beneficial effect of BCG?. Vaccine, 21(21–22), 2782–2790.

Quan, Y., Jeong, C. W., Kwak, C., Kim, H. H., Kim, H. S., & Ku, J. H. (2017). Dose, duration and strain of bacillus Calmette–Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials. Medicine, 96(42).

Kates, M., Nirschl, T., Sopko, N., Hahn, N., McConkey, D., Baras, A., ... & Bivalacqua, T. (2017). Intravesical BCG induces CD4 T Cell expansion in an immune competent model of bladder cancer, Cancer Immunol Res, 5 (2017) 594–603.

Ratliff, T. L., Ritchey, J. K., Yuan, J. J., Andriole, G. L., & Catalona, W. J. (1993). T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. The Journal of urology, 150(3), 1018–1023.

Bisetto, L. H. L., & Ciosak, S. I. (2017). Analysis of adverse events following immunization caused by immunization errors. Revista brasileira de enfermagem, 70(1), 87–95.

Amanati, A., Pouladfar, G., Kadivar, M. R., Dashti, A. S., Jafarpour, Z., Haghpanah, S., & Alborzi, A. (2017). A 25-year surveillance of disseminated Bacillus Calmette–Guérin disease treatment in children in Southern Iran. Medicine, 96(52), e9035.

Liaw, F., Tan, Y. Y., & Hendry, D. (2017). Systemic BCGosis following intravesical BCG instillation for bladder carcinoma. Clinical case reports, 5(10), 1569–1572.

Lukacs, S., Tschobotko, B., Szabo, N. A., & Symes, A. (2013). Systemic BCG-osis as a rare side effect of intravesical BCG treatment for superficial bladder cancer. Case reports in urology, 2013, 821526.

Rowland, R., & McShane, H. (2011). Tuberculosis vaccines in clinical trials. Expert review of vaccines, 10(5), 645–658.

Voss, G., Casimiro, D., Neyrolles, O., Williams, A., Kaufmann, S. H., McShane, H., ... & Fletcher, H. A. (2018). Progress and challenges in TB vaccine development. F1000Research, 7, 199.

Cardona, P. J., & Williams, A. (2017). Experimental animal modelling for TB vaccine development. International Journal of Infectious Diseases, 56, 268–273.

McShane, H., & Williams, A. (2014). A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis, 94(2), 105–110.

Layre, E., Mazurek, J., Gilleron, M. (2016). Glycolipid Presentation by CD1, eLS, Encyclopedia of Life Sciences 2016.

Behr, M. A., Wilson, M. A., Gill, W. P., Salamon, H., Schoolnik, G. K., Rane, S., & Small, P. M. (1999). Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science, 284(5419), 1520–1523.

Dey, B., Jain, R., Khera, A., Rao, V., Dhar, N., Gupta, U. D., ... & Tyagi, A. K. (2009). Boosting with a DNA vaccine expressing ESAT-6 (DNAE6) obliterates the protection imparted by recombinant BCG (rBCGE6) against aerosol Mycobacterium tuberculosis infection in guinea pigs. Vaccine, 28(1), 63–70.

Johansen, P., Fettelschoss, A., Amstutz, B., Selchow, P., Waeckerle-Men, Y., Keller, P., … & Sander, P. (2011). Relief from Zmp1-mediated arrest of phagosome maturation is associated with facilitated presentation and enhanced immunogenicity of mycobacterial antigens. Clinical and Vaccine Immunology, 18(6), 907–913.

Khatri, B., Whelan, A., Clifford, D., Petrera, A., Sander, P., & Vordermeier, H. M. (2014). BCG Δzmp1 vaccine induces enhanced antigen specific immune responses in cattle. Vaccine, 32(7), 779–784.

Nascimento, I. P., Rodriguez, D., Santos, C. C., Amaral, E. P., Rofatto, H. K., Junqueira-Kipnis, A. P., ... & Winter, N. (2017). Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis. Scientific reports, 7(1), 2109.

Gonzalo-Asensio, J., Marinova, D., Martin, C., & Aguilo, N. (2017). MTBVAC: Attenuating the human pathogen of tuberculosis towards a promising vaccine against the TB epidemic. Frontiers in immunology, 8, 1803.

Lahey, T., Laddy, D., Hill, K., Schaeffer, J., Hogg, A., Keeble, J., ... & von Reyn, C. F. (2016). Immunogenicity and protective efficacy of the DAR-901 booster vaccine in a murine model of tuberculosis. PloS one, 11(12), e0168521.

von Reyn, C. F., Lahey, T., Arbeit, R. D., Landry, B., Kailani, L., Adams, L. V., ... & Tvaroha, S. (2017). Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901. PloS one, 12(5), e0175215.

Tameris, M. D., Hatherill, M., Landry, B. S., Scriba, T. J., Snowden, M. A., Lockhart, S., ... & Mahomed, H. (2013). Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. The Lancet, 381(9871), 1021–1028.

Nemes, E., Hesseling, A. C., Tameris, M., Mauff, K., Downing, K., Mulenga, H., ... & Hanekom, W. A. (2017). Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial. Clinical Infectious Diseases, 66(4), 554–563.

Opublikowane

2018-06-22

Numer

Dział

Artykuł oryginalny

Jak cytować

Mazurek, J. (2018). Rola BCG w zapobieganiu gruźlicy i strategie prowadzące do zwiększenia jej immunogenności. Health Promotion & Physical Activity, 2(1), 17-22. https://doi.org/10.5604/01.3001.0012.1373

Podobne artykuły

Możesz również Rozpocznij zaawansowane wyszukiwanie podobieństw dla tego artykułu.